Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 1, 2010, Pages 33-42

  Koo, Jenn Hian ^a   Leong, Rupert W L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Colorectal cancer; Estrogen; Menopause sex

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR BETA; FLUOROURACIL; PLACEBO; PROGESTERONE;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 73449086997     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05992.x     Document Type: Review

References (123)

1. Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia: An Overview 2006. Cancer series no. 37, Cat. No. CAN 32. Canberra : AIHW, 2007.
2. Australian Institute of Health and Welfare & Australian Government Department of Health and Ageing. National Bowel Cancer Screening Program Monitoring Report 2008. Cancer Series 44. Cat. No. 40. Canberra : AIHW, 2008.
3. Mcmichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J. Natl Cancer Inst. 1980 65 : 1201 1207.
4. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer. Literature review for clinical application. Dis. Colon. Rectum. 1998 41 : 1033 1049.
5. McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following surgery for colorectal cancer. Br. J. Surg. 2003 90 : 711 715.
6. Chapuis PH, Dent OF, Fisher R et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br. J. Surg. 1985 72 : 698 702.
7. Kune GA, Kune S, Field B et al. Survival in patients with large-bowel cancer: a population-based investigation from the Melbourne Colorectal Cancer Study. Dis. Colon Rectum 1998 33 : 938 946.
8. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW, Melton LJ III. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987 60 : 2318 2324.
9. Wichmann MW, Muller C, Hornung HM, Lau-Werner U, Schildberg FW Colorectal Cancer Study Group. Gender differences in long-term survival of patients with colorectal cancer. Br. J. Surg. 2001 88 : 1092 1098.
10. DeCosse JJ, Ngoi S-S, Jacobson JS, Cennerazzo WJ. Gender and colorectal cancer. Eur. J. Cancer Prev. 1993 2 : 105 115.
11. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann. Intern. Med. 1990 113 : 779 788.
12. Doll R, Payne P, Waterhouse J. Cancer Incidence in Five Continents: A Technical Report. Springer-Verlag, Berlin : International Union Against Cancer, 1966.
13. Waterhouse J, Muir C, Shanmugaratnam K, Powell J. Cancer Incidence in Five Continents, Vol. II. IARC Publications No 15. Lyon : World Health Organization, 1982.
14. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer Incidence in Five Continents, Vol. V, IARC Scientific Publications No 88, Lyon : International Agency for Research on Cancer, 1987.
15. Curado MP, Edwards B, Shin HR, eds. Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon : IARC, 2007.
16. Grulich AE, McCredie M, Coates M. Cancer incidence in Asian migrants to New South Wales, Australia. Br. J. Cancer 1995 71 : 400 408.
17. Ziegler RG, Devesa SS, Fraumeni JF Jr. Epidemiological patterns of colorectal cancer. In : DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, PA : Lippincott, 1986 209 232.
18. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin. 2008 58 : 71 96.
19. Fernandez E, Bosetti C, La Vecchia C, Levi F, Fioretti F, Negri E. Sex differences in colorectal cancer mortality in Europe 1955-1996. Eur. J. Cancer Prev. 2000 9 : 99 104.
20. Fielding LP, Phillips RK, Fry JS, Hittinger R. Prediction of outcome after curative resection for large bowel cancer. Lancet 1986 18 : 904 906.
21. Wied U, Nilsson T, Knudsen JB, Sprechler M, Johansen A. Postoperative survival of patients with potentially curable cancer of the colon. Dis. Colon Rectum 1985 28 : 333 335.
22. Deans GT, Patterson CC, Parks TG et al. Colorectal carcinoma: importance of clinical and pathological factors in survival. Ann. R. Coll. Surg. Engl. 1994 76 : 59 64.
23. Albe X, Vassilakos P, Helfer-Guarnori K et al. Independent prognostic value in ploidy in colorectal cancer. A prospective study using image cytometry. Cancer 1990 66 : 1168 1175.
24. Ponz de Leon M, Sant M, Micheli A et al. Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study. Cancer 1992 69 : 626 635.
25. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br. J. Surg 2006 93 : 1115 1122.
26. Koo JH, Jalaludin B, Wong SKC, Kneebone A, Connor SJ, Leong RWL Improved survival in young women with colorectal cancer. Am. J. Gastroenterol. 2008 103 : 1488 1495.
27. Newland RC, Dent OF, Lyttle MN, Chapuis PH, Bokey EL. Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. Cancer 1994 73 : 2076 2082.
28. Australian Institute of Health and Welfare (AIHW). Heart, stroke and vascular diseases, Australian facts 2004. Canberra, Australia: AIHW and National Heart Foundation of Australia, 2004.
29. Lipska MA, Bisset IP, Parry BR, Merrie AEH. Anastomotic leakage after lower gastrointestinal anastomosis: men are at a higher risk. ANZ J. Surg. 2006 76 : 579 585.
30. Engel LW, Strauchen JA, Chiazze JR L, Heid M. Accuracy of death certification in an autopsied population with specific attention to malignant neoplasms and vascular disease. Am. J. Epidemiol. 1980 111 : 99 112.
31. McArdle CS, Hole DJ. Emergency presentation of colorectal cancer is associated with poor 5-year survival. Br. J. Surg. 2004 91 : 605 609.
32. Brenner H, Hoffmeister M, Arndt V, Haug U. Gender differences in colorectal cancer: implications for age at initiation of screening. Br. J. Cancer 2007 96 : 828 831.
33. Regula J, Rupinski M, Kraszewska E et al. Colonoscopy in colorectal cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 2006 355 : 1863 1872.
34. Hardcastle JD, Chamberlain JO, Robinson MHE et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996 348 : 1472 1477.
35. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM. Ederer F, for the Minnesota colon cancer control study. N. Engl. J. Med. 1993 328 : 1365 1371.
36. Kronborg O, Fenger C, Olsen OD, Joergensen O, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996 348 : 1467 1471.
37. Brown ML, Potosky AL, Thompson GB, Kessler LG. The knowledge and use of screening tests for colorectal and prostate cancer: data from the 1987 National Health Interview Survey. Prev. Med. 1990 19 : 562 574.
38. Seeff LC, Nadel MR, Klabunde CN et al. Patterns and predictors of colorectal cancer test use in the adult US population. Cancer 2004 100 : 2093 2103.
39. Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol. Biomarkers Prev. 2006 15 : 389 394.
40. Herold AH, Riker AI, Warner EA et al. Evidence of gender bias in patients undergoing flexible sigmoidoscopy. Cancer Detect. Prev. 1997 21 : 141 147.
41. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the National Health Interview Survey. Cancer 2003 97 : 1528 1540.
42. Codori A-M, Petersen GM, Miglioretti DL, Boyd P. Health belief and endoscopic screening for colorectal cancer: potential for cancer prevention. Prev. Med. 2001 33 : 128 136.
43. Brawarsky P, Brooks DR, Mucci LA. Correlates of colorectal testing in Massachusetts men and women. Prev. Med. 2003 36 : 85 91.
44. Vernon SW. Participation in colorectal cancer screening: a review. J. Natl Cancer Inst. 1997 89 : 1406 1422.
45. Friedemann-Sánchez G, Griffin JM, Partin MR. Gender differences in colorectal cancer screening barriers and information needs. Health Expectat. 2007 10 : 148 160.
46. Farraye FA, Wong M, Hurwitz S et al. Barriers to endoscopic colorectal cancer screening: are women different from men? Am. J. Gastroenterol. 2004 99 : 341 349.
47. Menees SB, Inadomi JM, Korsnes S, Elta GH. Women patients' preference for women physicians is a barrier to colon cancer screening. Gastrointest. Endosc. 2005 62 : 219 223.
48. Stockwell J, Woo P, Jacobsen BC et al. Determinants of colorectal cancer screening in women undergoing mammography. Am. J. Gastroenterol. 2003 98 : 1875 1880.
49. Brawarsky P, Brooks DR, Mucci LA, Wood PA. Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect. Prev. 2004 28 : 260 268.
50. Lemon SC, Zapka JG, Estabrook B, Erban S, Luckmann R. Screening for colorectal cancer in the front line. Am. J. Gastroenterol. 2003 98 : 141 147.
51. Sladden MJ, Ward JE. Australian general practitioners' views and use of colorectal cancer screening tests. Med. J. Aust. 1999 170 : 110 113.
52. Rabeneck L, Paszat LF, Li C. Risk factors for obstruction, perforation, or emergency admission at presentation in patients with colorectal cancer: a population-based study. Am. J. Gastroenterol. 2006 101 : 1098 1103.
53. Wolf BC, Salem RR, Sears HF et al. The expression of colorectal carcinoma-associated antigens in the normal colonic mucosa. An immunohistochemical analysis of regional distribution. Am. J. Pathol. 1989 135 : 111 119.
54. Caldero J, Campo E, Ascaso C, Ramos J, Panades MJ, Rene JM. Regional distribution of glycoconjugates in normal, transitional and neoplastic human colonic mucosa. A histochemical study using lectins. Virchows Arch A Pathol. Anat. Histopathol. 1989 415 : 347 356.
55. Shamsuddin AM, Phelps PC, Trump BF. Human large intestinal epithelium: light microscopy, histochemistry and ultrastructure. Hum. Pathol. 1982 13 : 790 803.
56. Liu LU, Holt PR, Krivosheyev V, Moss SF. Human right and left colon differ in epithelial cell apoptosis and in expression of Bak, a pro-apoptotic Bcl-2 homologue. Gut 1999 45 : 45 50.
57. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005 23 : 609 618.
58. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 58 : 5248 5257.
59. Samowitz WS, Curtin K, Ma K-N et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomarkers Prev. 2001 10 : 917 923.
60. Gervaz P, Bucher P, Morel P. Two colons - two cancers: paradigm shift and clinical implications. J. Surg. Oncol. 2004 88 : 261 266.
61. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcomes in young patients with colorectal cancer. N. Engl. J. Med. 2000 342 : 69 77.
62. Hawkins N, Norrie M, Cheong K et al. G island methylation in sporadic colorectal cancer and its relationship to microsatellite instability. Gastroenterology 2002 122 : 1376 1387.
63. Ward R, Meagher A, Tomlinson I et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer. Gut 2001 48 : 821 829.
64. Nelson RL, Dollear T, Freels S, Persky V. The relation of age, race and gender to the subsite location of colorectal carcinoma. Cancer 1997 80 : 193 197.
65. Takada H, Ohsawa T, Iwamoto S et al. Changing site distribution of colorectal cancer in Japan. Dis. Colon Rectum 2002 45 : 1249 1254.
66. Gonzalez EC, Roetzheim RG, Ferrante JM, Campbell R. Predictors of proximal vs distal colorectal cancers. Dis. Colon Rectum 2001 44 : 251 258.
67. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000 355 : 1745 1750.
68. Butcher D, Hassanein K, Dudgeon M, Rhodes J, Holmes FF. Female gender is a major determinant of changing subsite distribution of colorectal cancer with age. Cancer 1985 56 : 714 716.
69. Schoenfeld P, Cash B, Flood A et al. Lieberman D for the CONCeRN Study Investigators. Colonoscopic screening for average-risk women for colorectal neoplasia. N. Engl. J. Med. 2005 352 : 2061 2068.
70. McCashland TM, Brand R, Lyden E, de Garmo P. Gender differences in colorectal polyps and tumor. Am. J. Gastroenterol. 2001 96 : 882 886.
71. Campbell R, Ferrante J. Predictors of advanced stage colorectal cancer diagnosis: results of a population-based study. Cancer Detect. Prev. 2001 25 : 430 438.
72. Woods SE, Basho S, Engel A. The influence of gender on colorectal cancer stage: the state of Ohio, 1996-2001. J. Womens Health 2006 15 : 877 881.
73. Woods SE, Narayanan K, Engel A. The influence of gender on colon cancer stage. J. Womens Health 2005 14 : 478 483.
74. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999 116 : 1453 1456.
75. Aaltonen LA, Peltomaki P, Mecklin JP et al. Replication errors in benign and malignant tumors from hereditary nonpolyoposis colorectal cancer patients. Cancer Res. 1994 54 : 1645 1648.
76. Kinzler KW, Vogelstein B. Lessons from hereditary nonpolyposis colorectal cancer. Cell 1996 87 : 159 170.
77. Goecke T, Schulmann K, Engel C et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected by Lynch syndrome: a report by the German HNPCC consortium. J. Clin. Oncol. 2006 24 : 4285 4292.
78. Dunlop MG, Farrington SM, Carothers AD et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum. Mol. Genet 1997 6 : 105 110.
79. Vasen HF, Stormorken A, Menko FH et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of Hereditary Nonpolyposis Colorectal Cancer families. J. Clin. Oncol. 2001 19 : 4074 4080.
80. Wu AH, Shibata D, Yu MC, Lai MY, Ross RK. Dietary heterocyclic amines and microsatellite instability in colon adenocarcinomas. Carcinogenesis 2001 22 : 1681 1684.
81. Slattery ML, Curtin K, Anderson K et al. Association between cigarette smoking, lifestyle factors and microsatellite instability in colon tumors. J. Natl Cancer Inst. 2000 92 : 1831 1836.
82. Slattery ML, Potter JD, Curtin K et al. Estrogens reduce and withdrawal of estrogens increases risk of microsatellite instability-positive colon cancer. Cancer Res. 2001 61 : 126 130.
83. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998 58 : 3455 3460.
84. Thibodeau SN, French AJ, Cunningham JM et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 1998 58 : 1713 1718.
85. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am. J. Public Health 2000 90 : 1746 1754.
86. Beart RW, Steele GD Jr., Menck HR, Chmiel JS, Ocwieja KE, Winchester DP. Management and survival of patients with adenocarcinoma of the colon and rectum: a national survey of the Commission on Cancer. J. Am. Coll. Surg. 1995 181 : 225 236.
87. Sloan JA, Goldberg RM, Sargent DJ et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J. Clin. Oncol. 2002 20 : 1491 1498.
88. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2001 344 : 1196 1206.
89. Fietkau R, Rödel C, Hohenberger W et al. Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment centre, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int. J. Radiat. Oncol. Biol. Phys. 2007 67 : 1008 1019. (Pubitemid 46320080)
90. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N. Engl. J. Med. 2004 350 : 991 1004.
91. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 333.
92. Ritenbaugh C, Stanford JL, Wu LL et al. For the Women's Health Initiative Investigators. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative Randomized Clinical Trial. Cancer Epidemiol. Biomarkers Prev. 2008 17 : 2609 2618.
93. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med. 1999 106 : 574 582. (Pubitemid 29231110)
94. Grodstein F, Martinez ME, Platz EA et al. Postmenopausal hormone use and the risk of colorectal adenoma and cancer. Ann. Intern. Med. 1998 128 : 705 712.
95. Woodson K, Lanza E, Tangrea JA et al. For the Polyp Prevention Study Group. Hormone replacement therapy and colorectal adenoma recurrence among women in the randomized Polyp Prevention Trial. J. Natl Cancer Inst. 2001 93 : 1799 1805.
96. Slattery ML, Anderson K, Samowitz WS et al. Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA). Cancer Causes Control 1999 10 : 467 473.
97. Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J. Clin. Oncol. 2006 24 : 5680 5686.
98. Mandelson MT, Miglioretti D, Newcombe PA, Harrison R, Potter JD. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control 2003 14 : 979 984.
99. Kennelly R, Kavanagh DO, Hogan AM, Winter DC. Estrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol. 2008 9 : 385 391.
100. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor α and β: impact on human health. Mol. Aspects Med. 2006 27 : 299 402.
101. Hall JM, Couse JF, Korach KS. The multi-faceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 2001 276 : 36869 36872.
102. Di Leo A, Messa C, Cavallini A, Linsalata M. Estrogens and colorectal cancer. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2001 1 : 1 12.
103. Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res. 1992 12 : 1327 1330.
104. Issa JPJ, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the estrogen receptor CpG Island links aging and neoplasia in human colon. Nat. Genet. 1994 7 : 536 540.
105. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 1996 93 : 5925 5930.
106. Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor β is expressed in human colorectal adenocarcinoma. Hum. Pathol. 2001 32 : 940 944.
107. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor B in malignant human colon. Cancer Res. 2000 60 : 245 248.
108. Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of estrogen receptor β in colon cancer and its association with Dukes' staging. Oncol. Rep. 2005 14 : 17 21.
109. Konstantinopoulos PA, Kominea A, Vandoros G et al. Estrogen receptor beta (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur. J. Cancer 2003 39 : 1251 1258.
110. Notarnicola M, Gristina R, Messa C et al. Estrogen receptors and microsatellite instability in colorectal cancer patients. Cancer Lett. 2001 168 : 65 70.
111. Wong NACS, Malcomson RDG, Jodrell DI, Groome NP, Harrison DJ, Saunders PTK. ERβ isoforms expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J. Pathol. 2005 207 : 53 60.
112. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERB isoforms in colon cancer. CA Res. 2001 61 : 632 640.
113. Breivik J, Lothe RA, Meling GI, Rognum TO, Børresen-Dale A-L, Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int. J. Cancer (Pred. Oncol.) 1997 74 : 664 669.
114. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann. Intern. Med. 2004 140 : 184 188.
115. Australian Bureau of Statistics Regional Population Growth, Australia 3218.0, 2004-2005. Canberra, Australia: ABS, 2006.
116. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 2007 356 : 1670 1674.
117. Linsalata M, Russo F, Notarnicola M et al. Effects of genistein on the polyamine metabolism and cell growth in DLD-1 Human colon cancer cells. Nutr. Cancer 2005 52 : 84 93. (Pubitemid 41232653)
118. Hsu HH, Cheng SF, Wu CC et al. Apoptotic effects of overexpressed estrogen receptor beta on LoVo colon cancer cell is mediated by p53 signaling in a ligand-dependent manner. Chin. J. Physiol. 2006 49 : 110 116.
119. Wada-Hiraike O, Imamov O, Hiraike H et al. Role of estrogen receptor beta in colonic epithelium. Proc. Natl Acad. Sci. USA 2006 103 : 2959 2964.
120. McMichael AJ, Potter JD. Host factors in carcinogenesis: certain bile acid metabolic profiles that selectively increase the risk of proximal colon cancer. J. Natl Cancer Inst. 1985 75 : 185 191.
121. Everson GT, McKinley C, Kern F. Mechanisms of gallstone formation in women. Effects of exogenous estrogen and dietary cholesterol on hepatic lipid metabolism. J. Clin. Invest. 1991 87 : 237 246.
122. Campagnoli C, Biglia N, Altare F et al. Differential effects of oral conjugated and transdermal estradiol on insulin-like growth factor-1, growth hormone and sex hormone binding globulin serum levels. Gynecol. Endocrinol. 1993 7 : 251 258.
123. Tanaka Y, Kato K, Mibu R et al. Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression. Menopause 2008 15 : 442 453.